Enanta Pharmaceuticals (ENTA, Financial) announced plans to appeal a U.S. federal court decision favoring Pfizer (PFE) in a patent infringement case related to the COVID-19 antiviral drug, Paxlovid. The patent dispute began in 2022 when Enanta filed a lawsuit in Massachusetts, claiming that Pfizer's manufacture, use, and sale of Paxlovid infringed on its U.S. Patent No. 11358953.
The court ruled the patent invalid in response to Pfizer's motion for summary judgment. Enanta intends to take the case to the U.S. Court of Appeals. CEO Jay Luly expressed disappointment with the decision but remains committed to defending the company's inventions against unauthorized use through the appeals process.
